Supernus Pharmaceuticals, Inc.
SUPN
Positions held
Your positionsSUPN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Supernus Pharmaceuticals operates in a growing healthcare sector, focusing on specialty and generic drugs, which is expected to expand as demand for innovative treatments increases.
- In Q2 2026, Supernus reported a revenue increase of 5% compared to the previous quarter, reaching $219 million.
- The company's gross margin stood at 84.6% in Q2 2026, indicating strong profitability despite current operational challenges.
- The company has a high debt-to-equity ratio of 3.895, which may pose risks in financial stability and limit growth opportunities.
- Supernus has reported a negative profit margin of -0.13232, reflecting ongoing struggles to achieve profitability.
- The stock has a sell signal with a score of -10.00, indicating bearish market sentiment and a downward trend in performance.
Fundamentals
| Market cap | $2.45B | Enterprise value | $2.12B | Trailing P/E | — | Forward P/E | 9.45 |
| PEG | — | Price / book | 2.38 | Beta | 0.55 | Dividend yield | 0.00% |
| Revenue growth | 32.4% | Earnings growth | — | Gross margin | 72.9% | Operating margin | -2.5% |
| Profit margin | -13.2% | ROE | -10.5% | ROA | 0.4% | Debt / equity | 0.04 |
| Current ratio | 2.08 | Free cash flow | $84.61M | Analyst recommendation | none | Mean target | $61.75 |
| 52w high | $59.68 | 52w low | $40.51 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $219M | $208M | $212M | $192M | $165M | — |
| Op margin | -1.4% | -2.9% | 6.5% | -31.4% | 7.3% | — |
| Net income | -$58.4M | -$2.3M | -$4.1M | -$45.1M | $22.5M | — |
| Gross margin | 84.6% | 88.7% | 89.1% | 90.1% | 89.8% | — |
| Gross profit | $185M | $184M | $189M | $173M | $149M | — |
| Operating income | -$3.0M | -$5.9M | $13.8M | -$60.2M | $12.1M | — |
- Revenue +5% vs prior quarter ($219M vs $208M).
- Gross margin 84.6% (was 88.7% prior quarter).
- Operating margin expanded to -1.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $719M | $662M | $608M | $667M | — |
| Op margin | -5.1% | 11.4% | 2.2% | 6.8% | — |
| Net income | -$38.5M | $73.9M | $1.3M | $60.7M | — |
| Gross margin | 89.6% | 88.2% | 86.2% | 86.9% | — |
| Gross profit | $644M | $584M | $524M | $580M | — |
| Operating income | -$36.9M | $75.6M | $13.4M | $45.6M | — |
Headlines — watch
• [WARN · legal] 3 Cash-Heavy Stocks Walking a Fine Line
News
2026-09-30 · 1 Unprofitable Stock with Impressive Fundamentals and 2 We Avoid
2026-09-28 · Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
2026-09-28 · 2 Growth Stocks to Add to Your Roster and 1 We Question
2026-09-28 · Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
2026-09-25 · Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
2026-09-21 · 3 Reasons SUPN is Risky and 1 Stock to Buy Instead
2026-09-19 · Why Did Supernus Pharmaceuticals (SUPN) Move Today?
2026-09-18 · How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook
2026-09-18 · Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
2026-09-17 · Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger
2026-09-16 · 3 Cash-Heavy Stocks Walking a Fine Line
2026-09-08 · 1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds
Price (daily)
Full chart · RSI · MACD · patterns